Evaluation of a compression resistant matrix for recombinant human bone morphogenetic protein-2

被引:20
|
作者
Lu, Sheldon X. [1 ,4 ]
Fiorini, Tiago [1 ]
Lee, Jaebum [1 ]
Prasad, Hari S. [2 ]
Buxton, Amanda N. [3 ]
Bisch, Fredrick C. [4 ]
Dixon, Douglas R. [4 ]
Susin, Cristiano [1 ]
Wikesjoe, Ulf M. E. [1 ]
机构
[1] Georgia Regents Univ, LAPCR, Coll Dent Med, Augusta, GA 30912 USA
[2] Univ Minnesota, Hard Tissue Res Lab, Minneapolis, MN USA
[3] Medtron Spinal, Biol, Memphis, TN USA
[4] USA, Adv Educ Program Periodont, Ft Gordon, GA USA
关键词
biomaterials; bone; bone morphogenetic protein; osseointegration; tissue engineering; ALVEOLAR RIDGE AUGMENTATION; IMPLANT DEFECT MODEL; HISTOLOGIC OBSERVATIONS; CLINICAL-IMPLICATIONS; GRINDING TECHNIQUE; NONHUMAN-PRIMATES; TITANIUM IMPLANTS; BULKING AGENT; SPINE FUSION; BETA FAMILY;
D O I
10.1111/jcpe.12109
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background Previous studies document the therapeutic potential of recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier for indications in the axial and appendicular skeleton. Nevertheless, the ACS does not comprise structural integrity to adequately support bone formation for onlay indications. The objective of this study was to evaluate local bone formation and osseointegration following surgical implantation of rhBMP-2 soak-loaded onto a compression resistant matrix (CRM). Methods Routine, contralateral, critical-size, supraalveolar, peri-implant defects in five adult male Hound Labrador mongrel dogs received 0.8mg rhBMP-2 soak-loaded onto either the ACS (benchmark control) or a CRM (collagen/-TCP/hydroxyapatite) followed by submerged wound closure for primary intention healing. The animals were euthanized at 8weeks for histologic/histometric evaluation. Results Healing was uneventful albeit considerable initial swelling was observed for either treatment. Sites receiving rhBMP-2/CRM showed significantly increased bone area (20.0 +/- 0.9 versus 12.3 +/- 2.6mm2, p=0.03) and bone density (24.1 +/- 1.4% versus 14.6 +/- 2.0%, p=0.04) compared with those receiving rhBMP-2/ACS. There were no significant differences between treatments for new bone height and osseointegration. Woven and lamellar trabecular bone lined with abundant osteoid was observed for all sites. Inconsistent cortex formation confirmed the immature nature of the newly formed bone. Seroma formation was observed for both treatments (80-100% of the animals/implants). Sites receiving rhBMP-2/CRM showed residual ceramic granules undergoing biodegradation, including accumulation of foamy macrophages. Conclusions rhBMP-2/CRM supports bone formation of clinically relevant geometry. Longer observation intervals as well as dose variations appear necessary to capture maturation of the newly formed bone, elimination of residual ceramic granules and resolution of seroma formation(s).
引用
收藏
页码:688 / 697
页数:10
相关论文
共 50 条
  • [41] Promising Efficacy of Escherichia coli Recombinant Human Bone Morphogenetic Protein-2 in Collagen Sponge for Ectopic and Orthotopic Bone Formation and Comparison with Mammalian Cell Recombinant Human Bone Morphogenetic Protein-2
    Kim, In Sook
    Lee, Eui Nam
    Cho, Tae Hyung
    Song, Yun Mi
    Hwang, Soon Jung
    Oh, Ji Hye
    Park, Eun Kyung
    Koo, Tai Young
    Seo, Young-Kwon
    TISSUE ENGINEERING PART A, 2011, 17 (3-4) : 337 - 348
  • [42] Bone induction by Escherichia coli-derived recombinant human bone morphogenetic protein-2 compared with Chinese hamster ovary cell-derived recombinant human bone morphogenetic protein-2
    Bessho, K
    Konishi, Y
    Kaihara, S
    Fujimura, K
    Okubo, Y
    Iizuka, T
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2000, 38 (06): : 645 - 649
  • [43] EXPERIMENTAL SPINAL-FUSION WITH RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2
    SCHIMANDLE, JH
    BODEN, SD
    HUTTON, WC
    SPINE, 1995, 20 (12) : 1326 - 1337
  • [44] Preparation of recombinant human bone morphogenetic protein-2 and investigation of osteogenic activity
    Li, Guilong
    Wang, Jing
    Liu, Changsheng
    Huagong Xuebao/CIESC Journal, 2015, 66 (08): : 3183 - 3188
  • [45] Recombinant human bone morphogenetic protein-2 affects midsagittal sutural expansion
    Opperman, L. A.
    Xu Haisong
    Dechow, P. C.
    Buschang, P. H.
    Liu, S.
    CRANIOFACIAL SURGERY 13: PROCEEDINGS OF THE THIRTEEN CONGRESS OF THE INTERNATIONAL SOCIETY OF CRANIOFACIAL SURGERY AND PARIS DISTRACTION SYMPOSIUM, 2009, : 233 - 235
  • [46] Effect of recombinant human bone morphogenetic protein-2 on mandibular distraction osteogenesis
    Özeç, Y
    Öztürk, M
    Kylyç, E
    Yeler, H
    Göze, F
    Gümüs, C
    JOURNAL OF CRANIOFACIAL SURGERY, 2006, 17 (01) : 80 - 83
  • [47] Clinical application of recombinant human bone morphogenetic protein-2 in 4 dogs
    Milovancev, Milan
    Muir, Peter
    Manley, Paul A.
    Seeherman, Howard J.
    Schaefer, Susan
    VETERINARY SURGERY, 2007, 36 (02) : 132 - 140
  • [48] Surgical treatment of vertebral osteomyelitis with recombinant human bone morphogenetic protein-2
    O'Shaughnessy, Brian A.
    Kuklo, Timothy R.
    Ondra, Stephen L.
    SPINE, 2008, 33 (05) : E132 - E139
  • [49] Use of Recombinant Human Bone Morphogenetic Protein-2 in the Treatment of Degenerative Spondylolisthesis
    Schroeder, Gregory D.
    Hsu, Wellington K.
    Kepler, Christopher K.
    Kurd, Mark F.
    Vaccaro, Alexander R.
    Patel, Alpesh A.
    Savage, Jason W.
    SPINE, 2016, 41 (05) : 445 - 449
  • [50] Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications
    McKay, B
    Sandhu, HS
    SPINE, 2002, 27 (16) : S66 - S85